Objective: In order to assess the long-term (12 months) efficacy and safety of fenofibrate administered ... level was consistently above 300 mg/dL and low-density lipoprotein cholesterol (LDL ...
He is a listed applicant on a patent application in relation to the use of fenofibrate for treatment of diabetic retinopathy. He holds no shares, stocks or options in any pharmaceutical company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback